X
CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19). Learn More

Mitoxantrone (Teva®)

Common name: Mitoxantrone
Brand name: Teva®
 

What is Mitoxantrone?

Mitoxantrone is a chemotherapy drug used to treat advanced prostate cancer by interfering with the growth and reproduction of cancer cells. This therapy is used in combination with corticosteroids, such as prednisone or prednisolone.


How is Mitoxantrone administered?

Mitoxantrone is administered by injection.
 

What are possible side effects of this treatment?

Everyone responds differently to chemotherapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received mitoxantrone. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.

 
•    Bleeding / bruising
•    Diarrhea
•    Fatigue
•    Hair loss
•    Infection
•    Liver problems
•    Mouth sores
•    Nausea / vomiting
•    Pain, burning, redness, swelling at injection site
 
 

Is Mitoxantrone covered in my province or territory?

Provincial Coverage: Unknown    
    
Last Reviewed: July 2017
Prostate Cancer Canada and Canadian Cancer Society








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Canadian Cancer Society and Prostate Cancer Canada celebrate their amalgamation

February 3, 2020 (Toronto, ON) – On the eve of World Cancer Day, the Canadian Cancer Society (CCS) and Prostate Cancer Canada (PCC) have finalized their amalgamation.
More

1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More


Click here for news archive